Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Synergistic inhibition of salmeterol with fluticasone propionate or rolipram on stimulated eosinophil binding of β2 -integrin to ICAM-1 and cytosolic gIV-phospholipase A2 activation Source: Eur Respir J 2003; 22: Suppl. 45, 455s Year: 2003
Pharmacological properties of novel LTC4 synthase inhibitor Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action Source: Eur Respir J 2004; 24: Suppl. 48, 96s Year: 2004
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Lactose-β-sitosterol inhibits ovalbumin-induced asthmatic inflammation with no influence on nitric oxide pathway Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Effects of selective and non-selective cyclooxygenase inhibition on exhaled eicosanoids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004
NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Differential regulation of two distinct isoforms of inducible nitric oxide synthases by lipopolysaccharide in guinea-pig lung and colon Source: Eur Respir J 2001; 18: Suppl. 33, 197s Year: 2001
Inhibitors of NADPH-oxidase or nitric oxide synthase prevent airway hyperresponsiveness but not allergic inflammation in mice Source: Eur Respir J 2001; 18: Suppl. 33, 265s Year: 2001
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
Comparison of inhibitory potentials of pranlukast and zafirlukast on human liver CYP isoforms Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Comparison of roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone dipropionate in asthma control Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002
Effect of thromboxane A2 (TXA2 ) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Inhaled corticosteroids and leukotriene receptor antagonists induce protection against adenosine 5‘monophosphate induced bronchospasm in a synergic fashion Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Effects of acute nitric oxide synthase inhibition in a model of chronic airway inflammation in guinea pigs: correlation with capsaicin pretreatment Source: Eur Respir J 2002; 20: Suppl. 38, 383s Year: 2002
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Effects of inducible nitric oxide synthase and xanthine oxidase inhibitors on SEB-induced interstitial pneumonia in mice Source: Eur Respir J 2002; 19: 447-457 Year: 2002